Enzon Pharmaceuticals (ENZN)
Enzon Pharmaceuticals PE Ratio
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ENZN PE Ratio Range, Past 5 Years
| Minimum | 3.946 | Mar 2010 |
| Maximum | 526.50 | Dec 2009 |
| Average | 75.83 |
About Price to Earnings Ratio
The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A high PE ratio generally indicates increased demand because investors anticipate earnings growth in the future. The PE ratio has units of years, which can be interpreted as the number of years of earnings to pay back purchase price.
PE ratio is often referred to as the "multiple" because it demonstrates how much an investor is willing to pay for one dollar of earnings. PE Ratios are sometimes calculated using estimations of next year's earnings per share in the denominator. When this happens, it is usually noted.
Learn More
You may also be interested in these ENZN related companies
ENZN News
$ENZN filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3FPH
about 50 days ago by MarketBrief
about 50 days ago by MarketBrief
Icahn Capital's George Hebard Named as Director on Enzon Pharma (ENZN) Board
Feb 28, 5:17PM Street Insider
Feb 28, 5:17PM Street Insider
@TER_Intraday nice Fry Pan bottom in $ENZN since early Dec. Thanks for that.
about 119 days ago by 1nvestor
about 119 days ago by 1nvestor
EBR: Watchlist/worksheet/3Trading Ideas: $POT $IACI $ENZN http://stks.co/27m6
about 119 days ago by TER_Intraday
about 119 days ago by TER_Intraday
$ENZN http://stks.co/1VXa Biotech name. Flagging right under the 50MA. Watch the $7.15 level.
about 165 days ago by VexTrades
about 165 days ago by VexTrades
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
Dec 08, 6:15PM Marketwire
Dec 08, 6:15PM Marketwire
$ENZN http://stks.co/1Q88 Long setup for a short term trade. Tight price action in small wedge after recent strong buy volume
about 171 days ago by ToddinFL
about 171 days ago by ToddinFL
$ENZN http://stks.co/1ONJ Heavy short interest may have been taken out last week. Seth Klarman & Carl Icahn own 30% of shares.
about 172 days ago by drdebt
about 172 days ago by drdebt
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
Nov 12, 1:00PM Marketwire
Nov 12, 1:00PM Marketwire
Enzon COO Ralph Del Campo steps down, CFO Ana I. Stancic promoted to COO
Oct 17, 4:25PM FlyOnTheWall
Oct 17, 4:25PM FlyOnTheWall
Enzon Pharma (ENZN) Promotes CFO Stancic to COO; Forms Special Committee
Oct 17, 4:14PM Street Insider
Oct 17, 4:14PM Street Insider
Enzon Announces Promotion of CFO Ana I. Stancic to COO; Continues to Serve as CFO
Oct 17, 4:14PM Benzinga
Oct 17, 4:14PM Benzinga
Iridian Asset Management Raises Stake in Enzon Pharmaceuticals, Inc. (ENZN) to 11.6%
Oct 06, 1:47PM Street Insider
Oct 06, 1:47PM Street Insider
Enzon $ENZN to Cut Workforce by 48% to Support R&D Activities, Sees Q3 Charge ~$3M
about 246 days ago by Street_Insider
about 246 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ENZN | 6.31 | +0.15 | +2.44% | 294.09M |
| ENTR | 3.52 | +0.07 | +2.03% | 316.57M |
| ENTN | None | None | None | |
| ENSG | 24.87 | +0.08 | +0.32% | 525.80M |
| ENA | 0.1097 | -0.00 | -0.27% | 4.610M |
| EMN | 47.61 | +0.61 | +1.30% | 6.344B |
| EMITF | 2.20 | -0.08 | -3.50% | 54.76M |
| EMI | 13.48 | +0.03 | +0.22% | |
| EMC | 24.26 | +0.03 | +0.12% | 52.75B |
| ELX | 6.765 | -0.04 | -0.66% | 601.27M |
